Exploring the Controversy: Does NAD+ Supplementation Induce Cancer Risk?

The Peptique is LIVE! Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products. Have questions? Feel free to reach out to me: tarawest@westwellnessatx.com Want to get started the right way, but don't know where to start. Email me tarawest@westwellnessatx.com to set up a 30 minute $100 session to get your personalized protocol. A special discount on your first order will be included. These spots fill up fast so schedule today! Want the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over! Follow me on instagram @westwellnessatx Takeaways: This podcast episode marks the 50th installment, showcasing significant growth and listener engagement. The primary focus of today's discussion centers on the relationship between NAD and cancer risk. NAD is crucial for cellular functions including energy production, DNA repair, and immune response. Current research presents mixed results regarding NAD's role in cancer, demanding further investigation and caution. NAD supplementation may not inherently cause cancer but could influence existing cancer cell behavior. Listeners are encouraged to conduct their own research and consider their personal health situations regarding NAD usage. Research Links NAD+ biology, aging, immunity, DNA repair Covarrubias et al. “NAD+ metabolism and its roles in cellular processes during ageing” (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/ PMC Ghanem et al. “Inhibitors of NAD+ Production in Cancer Treatment” (NAMPT/NAPRT review). https://pmc.ncbi.nlm.nih.gov/articles/PMC10889166/ PMC Manickam et al. “Nampt: a new therapeutic target for modulating NAD metabolism in cancer and inflammation” (2025 review). https://cdnsciencepub.com/doi/10.1139/cjpp-2024-0400 Canadian Science Publishing Extracellular metabolism and cellular uptake (do IVs reach cells?) Gasparrini et al. “Enzymology of extracellular NAD metabolism” (ectoenzymes; NR/NMN/NAM import). https://pmc.ncbi.nlm.nih.gov/articles/PMC8038981/ PMC Yusri et al. “The role of NAD+ metabolism and its modulation” (2025 review; NR via ENTs; NMN dephosphorylation; SLC12A8 debate). https://www.nature.com/articles/s44324-025-00067-0 Nature Yaku et al. “NR and NMN: similarities and differences” (2025 perspective; NMN→NR conversion before uptake). https://www.science.org/doi/10.1126/sciadv.adr1538 Science Human IV NAD+ / IV NR data Grant et al. “A Pilot Study… during a 6-hour intravenous infusion of NAD+” (750 mg IV NAD+, plasma/urine kinetics, rapid early clearance, metabolite rise, tolerability). https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/PMC Randomized pilot: IV nicotinamide riboside (NR) 500 mg —acute safety. https://www.medrxiv.org/content/10.1101/2024.06.06.24308565v1.full-text MedRxiv Cancer signals—mixed preclinical findings Maric et al. “Bioluminescent probe… NR supplementation increased TNBC prevalence and brain metastases” (mouse). https://pubmed.ncbi.nlm.nih.gov/36371959/ PubMed Jiang et al. “NAD+ supplementation limits TNBC metastasis” (PDX model). https://pubmed.ncbi.nlm.nih.gov/36690678/ PubMed Mogol et al. “Targeting NAD+ Metabolism: Preclinical insights” (2024 endocrine review; tumor NAD+ dependencies). https://academic.oup.com/endo/article/165/5/bqae043/7639411 Oxford Academic Clinical-context commentary (regulatory and claims landscape) Guardian report on UK clinics advertising NAD+ infusions for addiction without robust evidence. https://www.theguardian.com/society/2025/feb/23/its-not-ethical-and-its-not-medical-how-uk-rehab-clinics-are-cashing-in-on-nad The Guardian